Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC
With significant Phase II results in ulcerative colitis, Arena is planning a Phase III program for its selective S1P receptor modulator etrasimod – a drug that it thinks can best Celgene's S1P-targeting therapy ozanimod on safety and possibly efficacy.
You may also be interested in...
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.
BMS’s S1P receptor modulator met endpoints in a Phase III trial treating patients with moderate to severe ulcerative colitis, boosting the drug class’s prospects in that condition.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.